PTCT FINANCIAL STATEMENTS

PTC Therapeutics Inc — balance sheet, income statement and cash flow trends

PTCTPTC Therapeutics Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value it Duel

Income Statement

Quarterly progression — trailing-twelve-month values

RevenueNet Income

Profit Funnel

Q1 2026 · TTM

Percentages are relative to revenue.

Key Figures

YoY change

Revenue827.1 M $-53.3%

Gross Profit643.8 M $-62.5%

Operating Income-67.7 M $-109.5%

EBITDA-119.6 M $-114.2%

Net Income-186.7 M $-131.4%

Peer Comparison· Biotechnology

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
PTCT	-53.3%	77.8%	-14.5%	-22.6%
TLX	56.3%	50.8%	3.0%	-0.9%
CSL	4.8%	48.6%	32.8%	9.2%
MSB	410.4%	-32.0%	-76.6%	-115.3%
Industry median	5.1%	84.0%	-105.8%	-125.7%

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
PTCT	-53.3%	77.8%	-14.5%	-22.6%
SRRK	—	—	—	—
ACLX	-79.4%	-64.8%	-888.3%	-1,027.3%
MIRM	50.2%	81.4%	-133.6%	-140.2%
LGND	51.2%	98.6%	81.0%	55.9%
RYTM	58.7%	89.4%	-83.2%	-93.3%
Industry median	5.1%	84.0%	-105.8%	-125.7%

Balance Sheet

Quarterly period-end values

Total AssetsTotal LiabilitiesEquity

Capital Structure

Q1 2026

Current Liabilities923.6 M $30%
Long-term Liabilities2.1 B $70%

Key Figures

YoY change

Total Assets2.9 B $+8.0%

Total Liabilities3 B $+7.3%

Total Equity-180.5 M $—

Cash & ST Investments1.9 B $-6.6%

Total Debt395.1 M $+1.4%

Net Debt-438.9 M $—

Peer Comparison· Biotechnology

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
PTCT	2.44	-218.9%	12.52	-6.3%
TLX	1.43	112.3%	13.13	35.1%
CSL	2.57	67.4%	2.22	49.2%
MSB	—	—	—	—
Industry median	5.90	10.9%	1.15	70.0%

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
PTCT	2.44	-218.9%	12.52	-6.3%
SRRK	8.64	74.5%	0.69	51.6%
ACLX	4.44	23.9%	1.79	66.6%
MIRM	2.09	133.5%	0.08	27.2%
LGND	21.28	45.3%	-1.47	65.1%
RYTM	4.17	184.7%	0.63	27.8%
Industry median	5.90	10.9%	1.15	70.0%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values

Operating Cash FlowCapital ExpendituresFree Cash Flow

Cash Flow Bridge

Q1 2026 · TTM

Key Figures

YoY change

Operating Cash Flow-217.9 M $-131.5%

Capital Expenditures46.1 M $+69.5%

Free Cash Flow-264 M $-138.9%

Dividends Paid——

Peer Comparison· Biotechnology

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
PTCT	-26.4%	-31.9%	5.6%	116.7%
TLX	-2.2%	-6.3%	4.1%	243.1%
CSL	24.0%	20.3%	3.7%	261.5%
MSB	-87.7%	-90.0%	2.3%	76.1%
Industry median	-88.0%	-90.9%	1.9%	81.5%

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
PTCT	-26.4%	-31.9%	5.6%	116.7%
SRRK	—	—	—	74.2%
ACLX	-943.5%	-953.9%	10.4%	91.8%
MIRM	-30.0%	-30.3%	0.3%	21.4%
LGND	45.0%	44.8%	0.2%	80.4%
RYTM	-55.0%	-55.5%	0.4%	59.0%
Industry median	-88.0%	-90.9%	1.9%	81.5%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on PTCT

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.